丙型肝炎病毒（HCV）的变革并非一蹴而就。
The HCV Revolution Did Not Happen Overnight.
作者信息
Kwong Ann D
机构信息
InnovaTID, Inc. , 125 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States.
出版信息
ACS Med Chem Lett. 2014 Mar 13;5(3):214-220. doi: 10.1021/ml500070q.
Abstract
The progress in HCV therapy in the last three years is similar to the progress that took HIV therapy ∼14 years. We are at the brink of approval for an all-oral drug combination that is dosed once daily as a single pill, has >95% efficacy, and is well tolerated. This article summarizes the path to this success and the challenges still ahead.
摘要
过去三年丙型肝炎病毒（HCV）治疗方面取得的进展与人类免疫缺陷病毒（HIV）治疗约14年所取得的进展相似。我们即将批准一种每日一次、单一片剂的全口服药物组合，其疗效超过95%，且耐受性良好。本文总结了取得这一成功的历程以及仍面临的挑战。
Zotero 插件